These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27492914)

  • 21. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
    Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
    Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: A meta-analysis of 11 randomized trials.
    Verdoia M; Khedi E; Ceccon C; Suryapranata H; De Luca G
    Int J Cardiol; 2018 Aug; 264():30-38. PubMed ID: 29776573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of short-term dual antiplatelet therapy (≤6 months) after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials.
    Misumida N; Abo-Aly M; Kim SM; Ogunbayo GO; Abdel-Latif A; Ziada KM
    Clin Cardiol; 2018 Nov; 41(11):1455-1462. PubMed ID: 30225978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome.
    Jang JY; Shin DH; Kim JS; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Park KW; Gwon HC; Kim HS; Jang Y
    PLoS One; 2018; 13(11):e0207386. PubMed ID: 30475845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of ≤6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation: A meta-analysis and meta-regression.
    Villablanca PA; Massera D; Mathew V; Bangalore S; Christia P; Perez I; Wan N; Schulz-Schüpke S; Briceno DF; Bortnick AE; Garcia MJ; Lucariello R; Menegus M; Pyo R; Wiley J; Ramakrishna H
    Medicine (Baltimore); 2016 Dec; 95(52):e5819. PubMed ID: 28033306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy: A Meta-analysis.
    Shah R; Rao SV; Latham SB; Kandzari DE
    JAMA Cardiol; 2018 Nov; 3(11):1050-1059. PubMed ID: 30383145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
    Pandit A; Giri S; Hakim FA; Fortuin FD
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Short-term Dual Antiplatelet Therapy after Implantation of Second-generation Drug-eluting Stents: A Meta-analysis and Systematic Review.
    Huang P; Yu Y; Han X; Yang Y
    Chin Med Sci J; 2017 Apr; 32(1):1-12. PubMed ID: 28399979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials.
    Gargiulo G; Windecker S; da Costa BR; Feres F; Hong MK; Gilard M; Kim HS; Colombo A; Bhatt DL; Kim BK; Morice MC; Park KW; Chieffo A; Palmerini T; Stone GW; Valgimigli M
    BMJ; 2016 Nov; 355():i5483. PubMed ID: 27811064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials.
    Verdoia M; Schaffer A; Barbieri L; Montalescot G; Collet JP; Colombo A; Suryapranata H; De Luca G
    Angiology; 2016 Mar; 67(3):224-38. PubMed ID: 26069031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duration of Dual Antiplatelet Therapy and Late Stent Thrombosis Following Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stents: A Simple Meta-Analysis of Randomized Controlled Trials.
    Lin BY; Li P; Wu P; Jiang RN; Bundhun PK; Ahmed MA
    Adv Ther; 2019 Nov; 36(11):3166-3173. PubMed ID: 31535329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials.
    Bulluck H; Kwok CS; Ryding AD; Loke YK
    Int J Cardiol; 2015 Feb; 181():331-9. PubMed ID: 25555272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
    Garg P; Galper BZ; Cohen DJ; Yeh RW; Mauri L
    Am Heart J; 2015 Feb; 169(2):222-233.e5. PubMed ID: 25641531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials.
    Tsoi MF; Cheung CL; Cheung TT; Wong IC; Kumana CR; Tse HF; Cheung BM
    Sci Rep; 2015 Aug; 5():13204. PubMed ID: 26278959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a meta-analysis of 3 randomized controlled trials.
    Liu M; Chen J; Huang D; Ke J; Tang W; Wu W
    J Cardiovasc Pharmacol; 2014 Jul; 64(1):41-6. PubMed ID: 24566464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials.
    Li H; Guo W; Dai W; Li L
    Drug Des Devel Ther; 2018; 12():1815-1825. PubMed ID: 29970956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
    Kim BK; Hong MK; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Kang TS; Park BE; Kang WC; Lee SH; Yoon JH; Hong BK; Kwon HM; Jang Y;
    J Am Coll Cardiol; 2012 Oct; 60(15):1340-8. PubMed ID: 22999717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: Insights From a Network Meta-Analysis of Randomized Trials.
    Kuno T; Ueyama H; Takagi H; Fox J; Bangalore S
    Cardiovasc Revasc Med; 2021 Jul; 28():50-56. PubMed ID: 32893157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial.
    Verdoia M; Suryapranata H; Damen S; Camaro C; Benit E; Barbieri L; Rasoul S; Liew HB; Polad J; Ahmad WAW; Zambahari R; Lalmand J; van der Schaaf RJ; Koh TH; Timmermans P; Dilling-Boer D; Veenstra LF; Van't Hof AWJ; Lee SWL; Roolvink V; Ligtenberg E; Postma S; Kolkman EJJ; Brouwer MA; Kedhi E; De Luca G
    J Thromb Thrombolysis; 2021 Oct; 52(3):797-807. PubMed ID: 33847862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.